entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 23:08:02 - browse：59

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： A Theranos scientist

knowledge

WSS

FDA seeking to stop procedures at two unregulated stem cell clinics

What we know about the American soldier detained in North Korea

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

A Q&A with the global head of Boehringer Ingelheim's innovation unit

ER docs worry over extreme heat as a 'mass casualty event'

Wikipedia

entertainment

knowledge

Psychedelics group wrestles with new pharma identity

Robert Kennedy Jr.'s presidential campaign attracts GOP

Peter Hotez and the public health issue of online harassment

What we know about the American soldier detained in North Korea

Heart attack and stroke risk calculators need revising

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

New air purifier tech could be key to improving indoor air quality

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Trump demands the U.S. pay no more for drugs than other countries … again

Stroke deaths set to near 10 million globally by 2050

focus

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

A Theranos scientist

Manchin plays down potential 3rd

US soldier in North Korean custody after crossing DMZ line

Manchin plays down potential 3rd

What to expect at HLTH 2023, the health care industry conference

focus

knowledge

explore

leisure time